Invitation to presentation of Q3 and 9M 2025 results
The Company will host a virtual Q3 and 9M 2025 presentation for investors, analysts and media at 08:30 CET on Thursday, 6 November, 2025.
ArcticZymes ASA Appoints New Exclusive European Distributor for its Bioprocess Nuclease Range
ArcticZymes is pleased to announce a new, exclusive European distributor agreement with Brenntag Specialists Pharma to compliment its existing commercial team, supply the SAN-HQ and M-SAN HQ product lines.
ArcticZymes Technologies Reports Q2 and H1 2025 Results: Biomanufacturing Growth Accelerates as Customer centric Strategy Gains Momentum
Tromsø, Norway, August 14, 2025 – ArcticZymes Technologies (OSE: AZT) today announced its financial results for the second quarter of 2025, highlighting progress in the Company’s commercial transformation. Total revenues reached NOK 28.9 million, up 5% year-over-year, led by strong 52% growth in the Biomanufacturing segment which contributed NOK 18.1 million. The quarter also marked a strategic milestone with the on-time launch of GMP-grade M-SAN HQ, a product developed in direct response to customer needs. M-SAN HQ GMP enables broader integration into viral vector manufacturing and reinforces ArcticZymes’ role as a reliable partner in gene therapy workflows.
ArcticZymes Technologies Launches GMP-Grade Nuclease for Next-Generation Viral Vector Manufacturing.
We are pleased to announce the expansion of our GMP product range, with the introduction of M-SAN HQ GMP, a new GMP grade nuclease specifically designed for viral vector manufacturing.
ArcticZymes Technologies ASA Q4 2024 Results & Presentation
Tromsø, Norway, February 13th, 2025 – ArcticZymes Technologies (OSE: AZT) reported total revenues of NOK 26.4 million and an EBITDA of NOK 2.7 million for the fourth quarter of 2024.